Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability - Wikidata - awgldk - TriplyDB

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

http://www.wikidata.org/entity/Q35532853

about

Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis How can mathematical models advance tuberculosis control in high HIV prevalence settings?Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis New anti-tuberculosis drugs and regimens: 2015 update In silico evaluation and exploration of antibiotic tuberculosis treatment regimens A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment The Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania.Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Therapy duration and long-term outcomes in extra-pulmonary tuberculosis.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.Moving Beyond Directly Observed Therapy for Tuberculosis.Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.The need to accelerate access to new drugs for multidrug-resistant tuberculosis.Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis.Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality

P2860

Q26781111-8EFF90D1-51E8-49B2-8892-3B8E84AAC1CF Q26824057-4B123281-FED9-4494-869B-3BBF6832CE3E Q28079207-34E95C4F-87ED-4931-866C-B235CD46350A Q28545109-54E84389-E8A9-4AD3-BB9B-F268303A77BE Q28550488-9FFEC36B-D00D-4DB4-B123-EDB0B8ACEB49 Q28550707-96BC2E42-8CAA-499E-85A6-781CA3B79348 Q28552186-18FAE7EB-495C-46BA-9012-330704BF4B00 Q28596775-CA4715C2-D801-49D1-A6EB-468DE955C4B0 Q28607283-80DFD221-3B67-4778-B95B-F3565FB7378B Q28649754-A66CA517-EAE4-457A-B307-7C3FBAC9A53F Q30279294-DBA3D068-72AB-44FC-A59F-E12770895FCD Q30395441-D8FFCA33-3691-4ABF-8200-8C933C1D4622 Q30411703-27691EBE-C99F-4809-B5A1-D77755F06143 Q33621748-B0A40598-4717-4A0F-9D29-E123B90578B2 Q33843657-B889ABB0-F40B-43E2-99EA-B963BF85CF63 Q33926262-7457DCC5-1335-4DB9-8081-816E3897376B Q34332805-F53E0E01-54E1-4810-9054-48862B9225E3 Q34466858-2354EE4D-0B06-4FB7-B4E0-2EC39A573EBF Q34729493-C92EA833-37E6-4821-A94C-84A4A810FF5A Q35104725-C870414C-00B0-40BA-9A40-DC2BD5520587 Q35167178-07F2DCC6-D2FD-46FD-88A2-D2A20E06AC99 Q35169089-4256D3BE-9381-41DB-9454-A436E4335A98 Q35584822-CCBC8370-2F0B-4EA3-ABEA-6A556F6A5268 Q35607890-FB5F228D-7631-4B95-A742-09093DC7B6BC Q35673445-9CDDB8BD-E44C-4675-9E08-903418D3F843 Q35699612-4B3B9ED7-56FF-4BA9-8948-4330F9D6E91D Q35776285-6E6D0EBA-6917-4BB4-B3D3-A5C574BC287C Q35806375-2B1CB7A7-AC72-494C-931B-FB227BB97856 Q35815071-C8D4EBB0-D7F2-445F-84D5-4FE95ADBC114 Q35859862-EC55A905-07F3-4F05-80CD-A44D3E20F0E5 Q35867681-5FF72609-9951-4F03-AFD8-B38F2B705CE8 Q35941434-3BA4602E-9230-4257-9089-4101DFE2A7A4 Q36020757-B96AAECD-218D-4E32-8025-6628AFE8FFD8 Q36172383-BF485FBF-8560-4C21-BF38-A88533158331 Q36172471-2D43B2F1-4047-4EB3-9770-8672D58C194C Q36364155-9BC659EA-6820-4A0D-9EA6-A193B1101E24 Q36379388-730C3064-0E67-4688-8D18-A6077E60F7B2 Q36439129-23B9BB9F-1BBA-42FE-B99E-D49A2EA9F58C Q36540893-B408A789-7EC8-46E0-8941-FEE86709E984 Q36540925-C5DD6939-7D09-47B3-9B6D-2A075BE51C1D

P2860

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

http://www.wikidata.org/entity/Q35532853

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@ast

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@en

type

label

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@ast

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@en

prefLabel

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@ast

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@en

P1433

Q35532853-B98FE230-5E60-4841-9772-067E8EC66E24

P1476

Q35532853-FBADC969-F51B-43E7-AB93-3CC63BC191E9

P2093

Q35532853-2F8C6E26-025D-424F-BE3A-601810DEDD75

Q35532853-3DA397B3-D6DD-4062-B259-9FD301198CD5

Q35532853-4195ED59-B01A-4875-82BB-AFF4488EFF97

P2860

Q35532853-09CBB5F9-139A-476D-8923-672110A7AD42

Q35532853-0D769D4A-C1F5-4A6C-9DF7-F2F7A199D672

Q35532853-0FBD47D9-77A7-43D5-B445-BAAEA9B5A200

Q35532853-142FEC29-A52F-478D-9C4B-382110D77B1B

Q35532853-19A8CF1A-E541-4ED5-9E40-7B69459C43C3

Q35532853-30F53480-95BC-4DBB-9647-5AB0A699F1CD

Q35532853-3107D5EF-7FAB-440F-A5DB-B21DAA74848D

Q35532853-3645B6A7-9DD1-45D5-8137-24CE0A1738FF

Q35532853-508806BB-DC10-4A28-BAE6-2582BA7B70CE

Q35532853-5CEB83FD-AC31-431D-AE86-8D951EA7A28C

P304

Q35532853-204123FA-056C-4BB5-B349-1C9D4CE75338

P31

Q35532853-17C90E42-7AF4-4ED5-9210-DD9E655A06B4

P356

Q35532853-B6E85C8F-8991-4391-BA43-E6CF898B31B2

P407

Q35532853-58A8902D-6B18-451E-A487-36FDB383F2F8

P433

Q35532853-DE15A8DA-D6DE-4E81-A8B9-3A4E2BA468DA

P478

Q35532853-5A07C484-F49F-4D80-8859-3EEDA3C77DA1

P50

Q35532853-51C276DA-2A87-4155-B266-401116CB77E3

Q35532853-BFDE0361-B2E5-4128-949E-367896B81E34

P577

Q35532853-E0817160-9DB2-4097-83D2-E686C69613B7

P5875

Q35532853-8AE298EB-9D1E-46C4-BED5-04CD97443993

P698

Q35532853-CF2AC841-1713-403E-8633-BF6414D5DC6B

P921

Q35532853-34B1F02F-2100-49DD-9D19-08D1A8A2C701

Q35532853-525F4956-65D4-41E2-9E74-752A9EB33AD2

Q35532853-F91C4A2D-EEAB-4113-8715-9EC83E2A8A5D

P932

Q35532853-7A414829-2FAE-454F-BB8B-E2FCE51D9633

P356

P1433

The Journal of Infectious Diseases

P1476

Multidrug-resistant tuberculos ...... nt pharmacokinetic variability

@en

P2093

Claudia Meek

http://www.w3.org/2001/XMLSchema#string

Jotam G Pasipanodya

http://www.w3.org/2001/XMLSchema#string

Richard Leff

http://www.w3.org/2001/XMLSchema#string

P2860

Directly observed therapy for treating tuberculosis

Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

The curious characteristics of pyrazinamide: a review

The effect of tuberculosis control in China

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa

Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Is pyrazinamide bactericidal against Mycobacterium tuberculosis?

P304

1951-1959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIR658

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

204

http://www.w3.org/2001/XMLSchema#string

P50

Shashikant Srivastava

P577

2011-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51736985

http://www.w3.org/2001/XMLSchema#string

P698

22021624

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance

P932

3209814

http://www.w3.org/2001/XMLSchema#string